AP
Amryt Pharma
UK - London
PharmaceuticalFocus: Orphan Specialty Drugs
Amryt Pharma is a life sciences company focused on Orphan Specialty Drugs.
Rare Diseases
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
Metreleptin
Generalised LipodystrophyClinical Trials (1)
NCT02325674MEASuRE: Metreleptin Effectiveness And Safety Registry
N/ALomitapide
Homozygous Familial HypercholesterolemiaClinical Trials (1)
NCT02135705LOWER: Lomitapide Observational Worldwide Evaluation Registry
N/AN/A
Clinical Trials (1)
NCT06423573A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez
N/Alomitapide
PregnancyClinical Trials (1)
NCT02399839Global Lomitapide Pregnancy Exposure Registry
N/AEvaluation of the Effect of Lomitapide Treatment on Major Adverse Cardiovascular Events (MACE) in Pa
Homozygous Familial Hypercholesterolemia (HoFH)Clinical Trials (1)
NCT06832371Evaluation of the Effect of Lomitapide Treatment on Major Adverse Cardiovascular Events (MACE) in Patients With Homozygous Familial Hypercholesterolemia
N/AMetreleptin
Lipomatosis, Multiple SymmetricalClinical Trials (1)
NCT05351164Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL)
Phase 2Oleogel-S10
Inherited Epidermolysis BullosaClinical Trials (1)
NCT01294241Oleogel-S10 in Wound Healing of Inherited Epidermolysis Bullosa (BEB-10)
Phase 2Phase 2
Clinical Trials (1)
NCT01294254Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 Versus Moist Wound Healing Dressing Alone in Accelerating the Epithelialization of Split Thickness Skin Graft Donor Sites
Phase 2Oleogel-S10 100 mg/g
Actinic KeratosesClinical Trials (1)
NCT00786994The Efficacy and Tolerability of Oleogel-S-10 in Patients With Actinic Keratoses
Phase 2Metreleptin
Familial Partial LipodystrophyClinical Trials (1)
NCT06679270Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
Phase 3Oleogel-S10, non-adhesive wound dressing
WoundsClinical Trials (1)
NCT01807650Oleogel-S10 in Wound Healing of Split-Thickness Skin Graft Donor Sites (BSG-12)
Phase 3metreleptin
Partial LipodystrophyClinical Trials (1)
NCT05164341Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL
Phase 3Oleogel-S10, non-adhesive wound dressing
WoundsClinical Trials (1)
NCT01657305Oleogel-S10 in Wound Healing of Split-Thickness Skin Graft Donor Sites (BSH-12)
Phase 3Oleogel-S10
Epidermolysis BullosaClinical Trials (1)
NCT03068780Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa
Phase 3Phase 3
Clinical Trials (1)
NCT04681170Efficacy and Safety of Lomitapide in Paediatric Patients With Homozygous Familial Hypercholesterolaemia (HoFH)
Phase 3Oleogel-S10 ointment
BurnsClinical Trials (1)
NCT01657292Oleogel-S10 Versus Standard of Care in Healing of Grade 2a Burn Wounds
Phase 3Metreleptin
Generalized LipodystrophyClinical Trials (1)
NCT06502990Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy
Phase 3Metreleptin
Partial LipodystrophyClinical Trials (1)
NCT06484868Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
Phase 4Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 2023
Portfolio: 18 clinical trials
Top TAs: Metabolic Diseases
Publications: 4 in PubMed